ME03557B - Privremena zaštiтa normalnih ćelija током hemoterapije - Google Patents
Privremena zaštiтa normalnih ćelija током hemoterapijeInfo
- Publication number
- ME03557B ME03557B MEP-2019-338A MEP2019338A ME03557B ME 03557 B ME03557 B ME 03557B ME P2019338 A MEP2019338 A ME P2019338A ME 03557 B ME03557 B ME 03557B
- Authority
- ME
- Montenegro
- Prior art keywords
- normal cells
- cells during
- transient protection
- during chemotherapy
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361798772P | 2013-03-15 | 2013-03-15 | |
US201361861374P | 2013-08-01 | 2013-08-01 | |
US201361911354P | 2013-12-03 | 2013-12-03 | |
US201461949786P | 2014-03-07 | 2014-03-07 | |
PCT/US2014/028685 WO2014144326A1 (en) | 2013-03-15 | 2014-03-14 | Transient protection of normal cells during chemotherapy |
EP14762438.1A EP2968290B1 (en) | 2013-03-15 | 2014-03-14 | Transient protection of normal cells during chemotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ME03557B true ME03557B (me) | 2020-07-20 |
Family
ID=51527871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2019-338A ME03557B (me) | 2013-03-15 | 2014-03-14 | Privremena zaštiтa normalnih ćelija током hemoterapije |
Country Status (18)
Country | Link |
---|---|
US (15) | US9487530B2 (me) |
EP (3) | EP3653209A1 (me) |
JP (9) | JP6337083B2 (me) |
CN (4) | CN108434149B (me) |
CA (2) | CA2906156C (me) |
CY (1) | CY1122434T1 (me) |
DK (1) | DK2968290T3 (me) |
ES (1) | ES2761406T3 (me) |
HK (3) | HK1222792A1 (me) |
HR (1) | HRP20192168T1 (me) |
HU (1) | HUE046653T2 (me) |
LT (1) | LT2968290T (me) |
ME (1) | ME03557B (me) |
PL (1) | PL2968290T3 (me) |
PT (1) | PT2968290T (me) |
RS (1) | RS59790B1 (me) |
SI (1) | SI2968290T1 (me) |
WO (2) | WO2014144847A2 (me) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
JP6337083B2 (ja) | 2013-03-15 | 2018-06-06 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | Rbポジティブ異常細胞増殖に対するhspc温存治療 |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US20160220569A1 (en) * | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
CR20170572A (es) | 2015-06-17 | 2018-03-20 | Pfizer | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa |
JP2018528952A (ja) * | 2015-08-28 | 2018-10-04 | ノバルティス アーゲー | Pi3k阻害剤のアルペリシブおよびcdk4/6阻害剤のリボシクリブを含む医薬組合せ、ならびにがんの治療/予防におけるその使用 |
JP6635374B2 (ja) * | 2015-12-18 | 2020-01-22 | 京都府公立大学法人 | 癌におけるリン酸化rbタンパク質を指標としたイリノテカン感受性予測法 |
WO2017161253A1 (en) * | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
CN112250670B (zh) | 2016-06-07 | 2021-06-08 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
JP2019520379A (ja) * | 2016-07-01 | 2019-07-18 | ジー1 セラピューティクス, インコーポレイテッド | ピリミジン系の抗増殖剤 |
WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
AU2017290362B2 (en) * | 2016-07-01 | 2021-08-05 | G1 Therapeutics, Inc. | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
BR112019003722A2 (pt) | 2016-08-23 | 2019-05-28 | Eisai R&D Man Co Ltd | terapias de combinação para o tratamento de carcinoma hepatocelular |
WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
WO2018129387A1 (en) * | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
EP3585389A4 (en) | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | TREATMENT OF EGFR MEDIATED CANCER WITH LESS SIDE EFFECTS |
SG11201908531WA (en) | 2017-03-16 | 2019-10-30 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of breast cancer |
CA3057582C (en) | 2017-03-23 | 2024-01-09 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN110913861B (zh) | 2017-06-29 | 2024-01-09 | G1治疗公司 | G1t38的形态学形式及其制造方法 |
EP3666774B1 (en) * | 2017-08-11 | 2022-05-11 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor |
WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
KR20200131246A (ko) | 2018-02-15 | 2020-11-23 | 누베이션 바이오 인크. | 키나제 억제제로서의 헤테로시클릭 화합물 |
CN114366743A (zh) * | 2018-04-09 | 2022-04-19 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
WO2020041770A1 (en) | 2018-08-24 | 2020-02-27 | G1 Therapeutics, Inc. | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
WO2020206035A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Treatment of cdk4/6 inhibitor resistant neoplastic disorders |
AU2020296087A1 (en) * | 2019-06-18 | 2022-01-27 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
AU2021273744A1 (en) * | 2020-05-19 | 2022-12-08 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
JP2023530096A (ja) * | 2020-06-11 | 2023-07-13 | ルネラ・バイオテック・インコーポレーテッド | 選択的cdk4/6阻害剤癌治療薬 |
EP4164653A1 (en) * | 2020-06-15 | 2023-04-19 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
WO1999065910A1 (en) | 1998-06-16 | 1999-12-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fused azepinone cyclin dependent kinase inhibitors |
EP1143943B1 (en) | 1999-01-29 | 2007-12-12 | The Board Of Trustees Of The University Of Illinois | USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY |
AU6314900A (en) | 1999-07-26 | 2001-02-13 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
AU2072201A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
ATE323704T1 (de) | 2000-06-26 | 2006-05-15 | Pfizer Prod Inc | Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe |
EP1325011B1 (en) | 2000-09-29 | 2004-05-06 | Eli Lilly And Company | Methods and compounds for treating proliferative diseases |
AU2002228692A1 (en) | 2000-12-01 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors |
AU2002305942B2 (en) | 2001-02-28 | 2006-10-26 | Onconova Therapeutics, Inc. | Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones |
CN101172158A (zh) | 2001-05-11 | 2008-05-07 | 得克萨斯州立大学董事会 | 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗 |
EA007395B3 (ru) | 2002-01-22 | 2018-02-28 | Уорнер-Ламберт Компани Ллс | 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ |
CA2495787A1 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
RS20050944A (en) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
KR100816945B1 (ko) | 2003-07-11 | 2008-03-25 | 워너-램버트 캄파니 엘엘씨 | 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염 |
ES2297502T3 (es) | 2003-10-23 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
JP2007530654A (ja) | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
WO2005100999A2 (en) | 2004-04-08 | 2005-10-27 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
WO2005117908A2 (en) | 2004-05-28 | 2005-12-15 | Gemin X Biotechnologies, Inc. | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
EP1845975A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
ZA200710379B (en) | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
WO2007065820A1 (en) | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
CA2631777A1 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
CN101415409B (zh) | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
CA2662587C (en) | 2006-09-11 | 2013-08-06 | Curis, Inc. | Quinazoline based egfr inhibitors |
JP2010513317A (ja) | 2006-12-14 | 2010-04-30 | パナシー ファーマシューティカルズ インコーポレーティッド | サイクリン依存性キナーゼの阻害による神経保護方法 |
JP2010514689A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | 癌、炎症およびウイルス感染症の処置のためのcdk阻害剤としてのヘテロアリール−ヘテロアリール化合物 |
EP2162451A4 (en) | 2007-06-25 | 2012-04-18 | Neurogen Corp | PIPERAZINYL-OXOALKYL-TETRAHYDRO-BETA-CARBOLINE AND RELATED ANALOGUE |
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
CN101945867A (zh) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物 |
ES2964764T3 (es) | 2008-07-29 | 2024-04-09 | Nerviano Medical Sciences Srl | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino |
WO2010020675A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
CA2738909A1 (en) * | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
EP3025724B1 (en) * | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
FR2957748B1 (fr) * | 2010-03-16 | 2012-09-07 | St Microelectronics Grenoble 2 | Composant electronique a montage en surface |
CN102299073A (zh) | 2010-06-25 | 2011-12-28 | 无锡华润上华半导体有限公司 | Vdmos器件及其制作方法 |
CN103429243B (zh) * | 2010-10-25 | 2016-06-08 | G1治疗公司 | Cdk抑制剂 |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
KR101968475B1 (ko) | 2010-11-02 | 2019-04-15 | 프로메가 코포레이션 | 코엘렌테라진 유도체 및 이를 이용하는 방법 |
EP2640394A4 (en) | 2010-11-17 | 2015-02-25 | Univ North Carolina | PROTECTION OF RENAL TISSUES AGAINST ISCHEMIA THROUGH INHIBITION OF CDK4 AND CDK6 PROLIFERATIVE KINASES |
ES2531465T3 (es) | 2010-12-23 | 2015-03-16 | Sanofi | Derivados de pirimidinona, su preparación y su utilización farmacéutica |
ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法 |
ME02382B (me) | 2011-07-27 | 2016-06-20 | Astrazeneca Ab | 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka |
WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
CA3163776A1 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
WO2014085318A1 (en) | 2012-11-28 | 2014-06-05 | Novartis Ag | Combination therapy |
JP6435315B2 (ja) * | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
JP6337083B2 (ja) * | 2013-03-15 | 2018-06-06 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | Rbポジティブ異常細胞増殖に対するhspc温存治療 |
US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
MX369503B (es) | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas. |
KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
US9796701B2 (en) | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US9374037B2 (en) | 2014-10-30 | 2016-06-21 | M/A-Com Technology Solutions Holdings, Inc. | Voltage-controlled oscillator with mask-selectable performance |
US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
AU2017290362B2 (en) * | 2016-07-01 | 2021-08-05 | G1 Therapeutics, Inc. | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
KR20190092478A (ko) * | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
US11541051B2 (en) * | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
US11395821B2 (en) * | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
CA3052810A1 (en) * | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
EP3735247A1 (en) | 2018-01-04 | 2020-11-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
WO2019136451A1 (en) * | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
CN114366743A (zh) * | 2018-04-09 | 2022-04-19 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
US11091522B2 (en) * | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
AU2020296087A1 (en) * | 2019-06-18 | 2022-01-27 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
-
2014
- 2014-03-14 JP JP2016503092A patent/JP6337083B2/ja active Active
- 2014-03-14 SI SI201431380T patent/SI2968290T1/sl unknown
- 2014-03-14 CN CN201810443050.5A patent/CN108434149B/zh active Active
- 2014-03-14 CA CA2906156A patent/CA2906156C/en active Active
- 2014-03-14 EP EP19198057.2A patent/EP3653209A1/en active Pending
- 2014-03-14 RS RS20191537A patent/RS59790B1/sr unknown
- 2014-03-14 PL PL14762438T patent/PL2968290T3/pl unknown
- 2014-03-14 EP EP14762438.1A patent/EP2968290B1/en active Active
- 2014-03-14 WO PCT/US2014/029429 patent/WO2014144847A2/en active Application Filing
- 2014-03-14 JP JP2016502870A patent/JP6430483B2/ja active Active
- 2014-03-14 ME MEP-2019-338A patent/ME03557B/me unknown
- 2014-03-14 LT LT14762438T patent/LT2968290T/lt unknown
- 2014-03-14 CN CN201810253672.1A patent/CN108283644B/zh active Active
- 2014-03-14 CA CA2906166A patent/CA2906166C/en active Active
- 2014-03-14 US US14/212,430 patent/US9487530B2/en active Active
- 2014-03-14 DK DK14762438T patent/DK2968290T3/da active
- 2014-03-14 HU HUE14762438A patent/HUE046653T2/hu unknown
- 2014-03-14 US US14/214,048 patent/US9527857B2/en active Active
- 2014-03-14 ES ES14762438T patent/ES2761406T3/es active Active
- 2014-03-14 CN CN201480027281.8A patent/CN105473140B/zh active Active
- 2014-03-14 US US14/212,911 patent/US9464092B2/en active Active
- 2014-03-14 WO PCT/US2014/028685 patent/WO2014144326A1/en active Application Filing
- 2014-03-14 EP EP14765105.3A patent/EP2968291A4/en active Pending
- 2014-03-14 CN CN201480027269.7A patent/CN105407889B/zh active Active
- 2014-03-14 PT PT147624381T patent/PT2968290T/pt unknown
-
2016
- 2016-09-18 HK HK16110953.6A patent/HK1222792A1/zh unknown
- 2016-10-06 HK HK16111632.3A patent/HK1223293A1/zh unknown
- 2016-10-07 US US15/288,878 patent/US9931345B2/en active Active
- 2016-11-03 US US15/342,990 patent/US10085992B2/en active Active
- 2016-12-21 US US15/387,083 patent/US10076523B2/en active Active
-
2018
- 2018-04-02 US US15/943,278 patent/US10660896B2/en active Active
- 2018-05-07 JP JP2018089382A patent/JP6517401B2/ja active Active
- 2018-08-24 US US16/112,362 patent/US10434104B2/en active Active
- 2018-08-24 US US16/112,360 patent/US10966984B2/en active Active
- 2018-10-30 JP JP2018204234A patent/JP6767456B2/ja active Active
- 2018-11-01 US US16/178,419 patent/US10925878B2/en active Active
-
2019
- 2019-01-17 HK HK19100793.8A patent/HK1258477A1/zh unknown
- 2019-04-16 JP JP2019077828A patent/JP6738933B6/ja active Active
- 2019-11-29 HR HRP20192168TT patent/HRP20192168T1/hr unknown
- 2019-12-11 CY CY20191101306T patent/CY1122434T1/el unknown
-
2020
- 2020-05-28 US US16/886,309 patent/US11040042B2/en active Active
- 2020-07-17 JP JP2020123189A patent/JP7250737B2/ja active Active
- 2020-09-16 JP JP2020155691A patent/JP7213854B2/ja active Active
-
2021
- 2021-02-22 US US17/181,638 patent/US11654148B2/en active Active
- 2021-04-05 US US17/222,873 patent/US11717523B2/en active Active
-
2023
- 2023-01-17 JP JP2023005413A patent/JP2023052449A/ja active Pending
- 2023-03-06 US US18/117,983 patent/US20230364098A1/en active Pending
- 2023-03-20 JP JP2023044746A patent/JP2023078341A/ja not_active Withdrawn
- 2023-08-07 US US18/231,091 patent/US20230381189A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258477A1 (zh) | 在化學療法期間對正常細胞的瞬時保護 | |
HK1223554A1 (zh) | 細胞 | |
IL267864B (en) | Overvoltage protection for electrical systems | |
GB2513727B (en) | Memory protection | |
EP3064388A4 (en) | BATTERY PROTECTION STRUCTURE | |
GB201415457D0 (en) | Short-circuit protection | |
PT3298918T (pt) | Melhorias na célula de proteção do crânio | |
EP2988346A4 (en) | CELL HOUSING | |
EP3004493A4 (en) | ENVIRONMENTAL PROTECTION FOR SUSPENDED POSTS | |
GB2514450B (en) | Lightning protection system | |
HK1222324A1 (zh) | 用於靜脈給藥的幹細胞組合物 | |
GB201310031D0 (en) | Cell | |
PL2759993T3 (pl) | Ochrona płytki dotykowej | |
GB201318498D0 (en) | Hydro Turbine | |
PL3057669T3 (pl) | Ochrona tryskacza | |
GB2518228B (en) | Structure Protector | |
PL3266944T3 (pl) | Układ ochrony przed wyciekiem | |
GB2518229B (en) | Structure Protector | |
GB2518227B (en) | Structure protector | |
TWM476425U (en) | Protection structure with microphone | |
GB201318231D0 (en) | Improvements relating to protection devices | |
GB201320928D0 (en) | Lightning protection for vehicles | |
GB201302056D0 (en) | Flood Protection System | |
TH1601002376B (th) | โครงสร้างการคุ้มกันแบตเตอรี่ | |
GB201317589D0 (en) | Cell |